Blar i forfatter "Aure, Miriam Ragle"

Viser treff 1-5 av 5

    • The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers 

      Knutsen, Erik; Lellahi, Seyed Mohammad; Aure, Miriam Ragle; Nord, Silje; Fismen, Silje; Larsen, Kenneth Bowitz; Tellez Gabriel, Marta; Hedberg, Annica; Bjørklund, Sunniva; Bofin, Anna M.; Mælandsmo, Gunhild Mari; Sørlie, Therese; Mortensen, Elin Synnøve; Perander, Maria (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-01-28)
      The long non-coding RNA <i>NEAT1</i> locus is transcribed into two overlapping isoforms, <i>NEAT1_1</i> and <i>NEAT1_2</i>, of which the latter is essential for the assembly of nuclear paraspeckles. <i>NEAT1</i> is abnormally expressed in a wide variety of human cancers. Emerging evidence suggests that the two isoforms have distinct functions in gene expression regulation, and recently it was shown ...

    • High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer 

      Normann, Lisa Svartdal; Haugen, Mads; Hongisto, Vesa; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Kristensen, Vessela N.; Tahiri, Andliena; Engebråten, Olav; Sahlberg, Guro Kristine Kleivi; Mælandsmo, Gunhild Mari (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-27)
      Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of this disease. Targeted treatment has improved outcome, but there is still a need for new therapeutic strategies as some patients respond poorly to treatment. Our aim was to identify compounds that substantially affect viability in HER2+ breast cancer cells in response to combinatorial treatment. We ...

    • LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer 

      Sas-Chen, Aldema; Aure, Miriam Ragle; Leibovich, Limor; Carvalho, Silvia; Enuka, Yehoshua; Körner, Cindy; Polycarpou-Schwarz, Maria; Lavi, Sara; Nevo, Nava; Kuznetsov, Yuri; Yuan, Justin; Azuaje, Francisco; Ulitsky, Igor; Diederichs, Sven; Wiemann, Stefan; Yakhini, Zohar; Kristensen, Vessela N.; Børresen-Dale, Anne-Lise; Yarden, Yosef; Sauer, Torill; Geisler, Jürgen; Hofvind, Solveig; Bathen, Tone Frost; Borgen, Elin; Engebråten, Olav; Fodstad, Øystein; Garred, Øystein; Geitvik, Gry; Kåresen, Rolf; Naume, Bjørn; Mælandsmo, Gunhild; Russnes, Hege Elisabeth Giercksky; Schlichting, Ellen; Sørlie, Therese; Lingjærde, Ole Christian; Sahlberg, Kristine Kleivi; Skjerven, Helle; Fritzman, Britt (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-09-01)
      Long noncoding RNAs (lncRNAs) are emerging as regulators of gene expression in pathogenesis, including cancer. Recently, lncRNAs have been implicated in progression of specific subtypes of breast cancer. One aggressive, basal-like subtype associates with increased EGFR signaling, while another, the HER2-enriched subtype, engages a kin of EGFR Based on the premise that EGFR-regulated lncRNAs might ...

    • MicroRNA in combination with HER2-targeting drugs reduces breast cancer cell viability in vitro 

      Svartdal, Lisa Gregusson; Aure, Miriam Ragle; Leivonen, Suvi-Katri; Haugen, Mads Haugland; Hongisto, Vesa; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari; Sahlberg, Kristine Kleivi (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-05-25)
      HER2-positive (HER2 +) breast cancer patients that do not respond to targeted treatment have a poor prognosis. The effects of targeted treatment on endogenous microRNA (miRNA) expression levels are unclear. We report that responsive HER2 + breast cancer cell lines had a higher number of miRNAs with altered expression after treatment with trastuzumab and lapatinib compared to poorly responsive cell ...

    • miR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy 

      Normann, Lisa Svartdal; Haugen, Mads Haugland; Aure, Miriam Ragle; Kristensen, Vessela N.; Mælandsmo, Gunhild Mari; Sahlberg, Kristine Kleivi (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-03-01)
      Purpose: Human epidermal growth factor receptor 2 positive (HER2+) breast cancers responding poorly to targeted therapy need improved treatment options. miR-101-5p has shown tumor-suppressive properties in multiple cancer forms, and we assessed the effect and mechanism of action of this miRNA in HER2+ breast cancer.<p> <p>Methods: Expression levels of miR-101-5p in two clinical datasets, TCGA and ...